Receptor Signaling in Transitional B Cells Protease Sppl2a Is Critical

Total Page:16

File Type:pdf, Size:1020Kb

Receptor Signaling in Transitional B Cells Protease Sppl2a Is Critical Processing of CD74 by the Intramembrane Protease SPPL2a Is Critical for B Cell Receptor Signaling in Transitional B Cells This information is current as Susann Hüttl, Kathrin Kläsener, Michaela Schweizer, Janna of September 25, 2021. Schneppenheim, Hans-Heinrich Oberg, Dieter Kabelitz, Michael Reth, Paul Saftig and Bernd Schröder J Immunol 2015; 195:1548-1563; Prepublished online 8 July 2015; doi: 10.4049/jimmunol.1403171 Downloaded from http://www.jimmunol.org/content/195/4/1548 Supplementary http://www.jimmunol.org/content/suppl/2015/07/08/jimmunol.140317 Material 1.DCSupplemental http://www.jimmunol.org/ References This article cites 84 articles, 43 of which you can access for free at: http://www.jimmunol.org/content/195/4/1548.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 25, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2015 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Processing of CD74 by the Intramembrane Protease SPPL2a Is Critical for B Cell Receptor Signaling in Transitional B Cells Susann Huttl,*€ Kathrin Kla¨sener,†,‡,x Michaela Schweizer,{ Janna Schneppenheim,‖ Hans-Heinrich Oberg,# Dieter Kabelitz,# Michael Reth,†,‡,x Paul Saftig,* and Bernd Schro¨der* The invariant chain (CD74), a chaperone in MHC class II–mediated Ag presentation, is sequentially processed by different endosomal proteases. We reported recently that clearance of the final membrane-bound N-terminal fragment (NTF) of CD74 is mediated by the intramembrane protease signal peptide peptidase-like (SPPL)2a, a process critical for B cell development. In mice, SPPL2a deficiency provokes the accumulation of this NTF in endocytic vesicles, which leads to a B cell maturation arrest at Downloaded from the transitional 1 stage. To define the underlying mechanism, we analyzed the impact of SPPL2a deficiency on signaling pathways involved in B cell homeostasis. We demonstrate that tonic as well as BCR-induced activation of the PI3K/Akt pathway is massively compromised in SPPL2a2/2 B cells and identify this as major cause of the B cell maturation defect in these mice. Altered BCR trafficking induces a reduction of surface IgM in SPPL2a-deficient B cells, leading to a diminished signal transmission via the BCR and the tyrosine kinase Syk. We provide evidence that in SPPL2a2/2 mice impaired BCR signaling is to a great extent provoked by the accumulating CD74 NTF, which can interact with the BCR and Syk, and that impaired PI3K/Akt signaling and reduced http://www.jimmunol.org/ surface IgM are not directly linked processes. In line with disturbances in PI3K/Akt signaling, SPPL2a2/2 B cells show a dysreg- ulation of the transcription factor FOXO1, causing elevated transcription of proapoptotic genes. We conclude that SPPL2a- mediated processing of CD74 NTF is indispensable to maintain appropriate levels of tonic BCR signaling to promote B cell maturation. The Journal of Immunology, 2015, 195: 1548–1563. he invariant chain (CD74) is an essential component of MHCII. Interference with this process, for example by the absence the MHC class II (MHCII) Ag presentation pathway fa- of the cysteine protease cathepsin S, significantly impairs Ag T cilitating assembly and endosomal targeting of the MHCII presentation by MHCII (1). Beyond its canonical function as by guest on September 25, 2021 complexes (1). CD74 binds to the MHCII peptide-binding groove chaperone of MHCII, CD74 was reported to modulate endocytic with its CLIP segment and prevents premature peptide binding. In trafficking and endosomal maturation in APCs (2–4). Further- Ag-processing compartments, the luminal domain of CD74 is more, the regulation of dendritic cell migration (5) and also the sequentially degraded by endosomal proteases, thereby releasing cellular responses to the proinflammatory cytokine macrophage migration inhibitory factor are dependent on CD74 as cell surface receptor (6). Coreceptors such as CD44 (7) or CXCR4 (8) are *Biochemical Institute, Christian Albrechts University of Kiel, D-24118 Kiel, required to initiate signal transduction following migration in- Germany; †BIOSS Centre for Biological Signalling Studies, University of Freiburg, hibitory factor binding to CD74. Interestingly, enhanced expres- D-79104 Freiburg, Germany; ‡Institute for Biology III, Faculty of Biology, University x sion levels of CD74 have been observed in different forms of of Freiburg, D-79104 Freiburg, Germany; Max Planck Institute for Immunobiology and Epigenetics, D-79108 Freiburg, Germany; {Center for Molecular Neurobiology, malignancies and are positively correlated with increased cellular ‖ University Medical Center Hamburg–Eppendorf, D-20246 Hamburg, Germany; In- migration and/or invasion (9–11). In this context, overexpression stitute of Anatomy, Christian Albrechts University of Kiel, D-24118 Kiel, Germany; and #Institute of Immunology, Christian Albrechts University of Kiel, D-24105 Kiel, of CD74 in HEK293 cells activates central signaling pathways Germany such as the PI3K/Akt and the MAPK/ERK cascades (12). Received for publication December 22, 2014. Accepted for publication June 9, 2015. We recently found that clearance of the final membrane-bound This work was supported by the Deutsche Forschungsgemeinschaft as part of Grant N-terminal fragment (NTF) of CD74 requires activity of the SFB877 (Project B7, to B.S.) and the Cluster of Excellence “Inflammation at Inter- GxGD-type intramembrane protease signal peptide peptidase-like faces” as well as by Deutsche Forschungsgemeinschaft Grant SCHR 1284/1-1. This (SPPL)2a (13), but not of its closely related homolog SPPL2b work was also supported by the Excellence Initiative of the German Federal and State Governments (Grant EXC 294), European Research Council Grant 32297, and by (14). This unique role of SPPL2a is also conserved in human Deutsche Forschungsgemeinschaft Grants SFB746 and TRR130. B cells (15). SPPL2a is part of the SPP/SPPL protease family with Address correspondence and reprint requests to Dr. Bernd Schro¨der, Biochemical specificity for transmembrane proteins in type II orientation (16). Institute, Christian Albrechts University of Kiel, Otto-Hahn-Platz 9, D-24118 Kiel, Within this family, SPPL2a is unique with its localization in Germany. E-mail address: [email protected] lysosomes/late endosomes (14, 17). Additional substrates of SPPL2a The online version of this article contains supplemental material. include TNF-a, Fas ligand, Bri2, and TMEM106B (16, 18). Abbreviations used in this article: EEF2, eukaryotic elongation factor 2; MFI, median fluorescence intensity; MHCII, MHC class II; NTF, N-terminal fragment; PFA, para- In SPPL2a-deficient B cells, unprocessed CD74 NTF accumu- formaldehyde; PIP3, phosphatidylinositol 3,4,5-trisphosphate; PLA, proximity liga- lates in significant amounts, leading to an arrest of B cell matu- tion assay; qRT-PCR, quantitative real-time PCR; SPP, signal peptide peptidase; ration at the transitional stage 1 (T1) in mice (13). Furthermore, SPPL, signal peptide peptidase-like; T1, transitional stage 1. functionality of the remaining B cells is considerably impaired Copyright Ó 2015 by The American Association of Immunologists, Inc. 0022-1767/15/$25.00 with regard to Ig production. Major phenotypic findings described www.jimmunol.org/cgi/doi/10.4049/jimmunol.1403171 The Journal of Immunology 1549 in this study were additionally confirmed in two SPPL2a mutant 100 U/ml penicillin, and 100 mg/ml streptomycin in the presence of 5 ng/ml mouse lines (19, 20). Additional ablation of CD74 in SPPL2a2/2 IL-7 (BioLegend) for 4 d as described in Rowland et al. (22). Prior to further mice improved B cell maturation and function, indicating that analysis of signaling pathways, cells were washed twice in PBS and cultured overnight in fresh complete IMDM without IL-7. the B cell phenotype of these mice can be mainly ascribed to 2 2 the incomplete turnover of the CD74 NTF (13). In SPPL2a / BCR stimulation B cells, the unprocessed CD74 NTF accumulates in endosomal Activation of the BCR was achieved by incubating the cells in the presence compartments where it disturbs membrane trafficking, leading to of 10 mg/ml goat anti-mouse IgG/IgM F(ab9)2 (Dianova). For analysis of a highly increased abundance of endosome-derived vacuoles in signal transduction pathways, cells were stimulated in 500 ml RPMI 1640 these cells. Hence, control of CD74 NTF levels by the intra- medium (Sigma-Aldrich) or 500 ml PBS for 5 min at 37˚C followed by membrane protease SPPL2a is essential for B cell maturation and Western blot or flow cytometric determination, respectively, of kinase activation (Syk, ERK1/2, Akt). Depending on the applied readout system, survival as well as the integrity of the endocytic system. In light of stimulation experiments were either performed with purified
Recommended publications
  • CD74 Targeted Nanoparticles As Dexamethasone Delivery System for B Lymphoid Malignancies
    CD74 targeted nanoparticles as Dexamethasone Delivery System for B lymphoid malignancies DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Georgia Triantafillou, MPH Integrated Biomedical Sciences Graduate Program The Ohio State University 2011 Dissertation Committee John C. Byrd, MD, advisor Natarajan Muthusamy, PhD co-advisor Robert J.Lee, PhD, co-advisor Mitch A.Phelps, PhD, co-advisor Guido Marcucci, MD committee member Susheela Tridandapani, PhD committee member Copyright page Georgia Triantafillou 2011 ABSTRACT Chronic Lymphocytic Leukemia (CLL) is the most common adult leukemia and is not curable with standard therapy. In CLL the B lymphocytes appear morphologically mature but immunologically express less mature B cell makers. Specifically, the CLL B cells co-express surface antigens including CD19, CD20, CD5, CD23. Due to nonspecific delivery of the drugs to malignant as well as normal cells, patients experience numerous side effects. Targeted drug delivery to cancer cells is a desirable goal for all anti cancer strategies. Corticosteroids have been proven to be a beneficial and well established part of CLL treatment. Dexamethasone(DEX) is frequently used in CLL therapies as well as other malignancies and antiinflammatory diseases. However, DEX nonspecifically enters all tissues inducing various toxicities to patients. Therefore, DEX treatment is often discontinued or not administered to certain patients. We aimed to deliver this efficient clinical agent via a targeted delivery vehicle and examine its effect on its target B-CLL cells. The main scope of the work presented is the creation of a sterically stable nanoparticle, an ii immunoliposome (ILP), that has DEX encapsulated in its interior and a monoclonal antibody(Mab) in its exterior targeting CLL B cells expressing the surface antigen that is recognized by the Mab.
    [Show full text]
  • Single-Cell RNA Sequencing Identifies Candidate Renal
    BASIC RESEARCH www.jasn.org Single-Cell RNA Sequencing Identifies Candidate Renal Resident Macrophage Gene Expression Signatures across Species Kurt A. Zimmerman,1 Melissa R. Bentley,1 Jeremie M. Lever ,2 Zhang Li,1 David K. Crossman,3 Cheng Jack Song,1 Shanrun Liu,4 Michael R. Crowley,3 James F. George,5 Michal Mrug,2,6 and Bradley K. Yoder1 1Department of Cell, Developmental, and Integrative Biology, 2Division of Nephrology, Department of Medicine, 3Department of Genetics, 4Department of Biochemistry and Molecular Genetics, and 5Division of Cardiothoracic Surgery, Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama; and 6Department of Veterans Affairs Medical Center, Birmingham, Alabama ABSTRACT Background Resident macrophages regulate homeostatic and disease processes in multiple tissues, in- cluding the kidney. Despite having well defined markers to identify these cells in mice, technical limita- tions have prevented identification of a similar cell type across species. The inability to identify resident macrophage populations across species hinders the translation of data obtained from animal model to human patients. Methods As an entry point to determine novel markers that could identify resident macrophages across species, we performed single-cell RNA sequencing (scRNAseq) analysis of all T and B cell–negative CD45+ innate immune cells in mouse, rat, pig, and human kidney tissue. Results We identified genes with enriched expression in mouse renal resident macrophages that were also present in candidate resident macrophage populations across species. Using the scRNAseq data, we defined a novel set of possible cell surface markers (Cd74 and Cd81) for these candidate kidney resident macrophages. We confirmed, using parabiosis and flow cytometry, that these proteins are indeed enriched in mouse resident macrophages.
    [Show full text]
  • Single-Cell RNA Sequencing Demonstrates the Molecular and Cellular Reprogramming of Metastatic Lung Adenocarcinoma
    ARTICLE https://doi.org/10.1038/s41467-020-16164-1 OPEN Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma Nayoung Kim 1,2,3,13, Hong Kwan Kim4,13, Kyungjong Lee 5,13, Yourae Hong 1,6, Jong Ho Cho4, Jung Won Choi7, Jung-Il Lee7, Yeon-Lim Suh8,BoMiKu9, Hye Hyeon Eum 1,2,3, Soyean Choi 1, Yoon-La Choi6,10,11, Je-Gun Joung1, Woong-Yang Park 1,2,6, Hyun Ae Jung12, Jong-Mu Sun12, Se-Hoon Lee12, ✉ ✉ Jin Seok Ahn12, Keunchil Park12, Myung-Ju Ahn 12 & Hae-Ock Lee 1,2,3,6 1234567890():,; Advanced metastatic cancer poses utmost clinical challenges and may present molecular and cellular features distinct from an early-stage cancer. Herein, we present single-cell tran- scriptome profiling of metastatic lung adenocarcinoma, the most prevalent histological lung cancer type diagnosed at stage IV in over 40% of all cases. From 208,506 cells populating the normal tissues or early to metastatic stage cancer in 44 patients, we identify a cancer cell subtype deviating from the normal differentiation trajectory and dominating the metastatic stage. In all stages, the stromal and immune cell dynamics reveal ontological and functional changes that create a pro-tumoral and immunosuppressive microenvironment. Normal resident myeloid cell populations are gradually replaced with monocyte-derived macrophages and dendritic cells, along with T-cell exhaustion. This extensive single-cell analysis enhances our understanding of molecular and cellular dynamics in metastatic lung cancer and reveals potential diagnostic and therapeutic targets in cancer-microenvironment interactions. 1 Samsung Genome Institute, Samsung Medical Center, Seoul 06351, Korea.
    [Show full text]
  • CD29 Identifies IFN-Γ–Producing Human CD8+ T Cells With
    + CD29 identifies IFN-γ–producing human CD8 T cells with an increased cytotoxic potential Benoît P. Nicoleta,b, Aurélie Guislaina,b, Floris P. J. van Alphenc, Raquel Gomez-Eerlandd, Ton N. M. Schumacherd, Maartje van den Biggelaarc,e, and Monika C. Wolkersa,b,1 aDepartment of Hematopoiesis, Sanquin Research, 1066 CX Amsterdam, The Netherlands; bLandsteiner Laboratory, Oncode Institute, Amsterdam University Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands; cDepartment of Research Facilities, Sanquin Research, 1066 CX Amsterdam, The Netherlands; dDivision of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands; and eDepartment of Molecular and Cellular Haemostasis, Sanquin Research, 1066 CX Amsterdam, The Netherlands Edited by Anjana Rao, La Jolla Institute for Allergy and Immunology, La Jolla, CA, and approved February 12, 2020 (received for review August 12, 2019) Cytotoxic CD8+ T cells can effectively kill target cells by producing therefore developed a protocol that allowed for efficient iso- cytokines, chemokines, and granzymes. Expression of these effector lation of RNA and protein from fluorescence-activated cell molecules is however highly divergent, and tools that identify and sorting (FACS)-sorted fixed T cells after intracellular cytokine + preselect CD8 T cells with a cytotoxic expression profile are lacking. staining. With this top-down approach, we performed an un- + Human CD8 T cells can be divided into IFN-γ– and IL-2–producing biased RNA-sequencing (RNA-seq) and mass spectrometry cells. Unbiased transcriptomics and proteomics analysis on cytokine- γ– – + + (MS) analyses on IFN- and IL-2 producing primary human producing fixed CD8 T cells revealed that IL-2 cells produce helper + + + CD8 Tcells.
    [Show full text]
  • The Chemokine System in Innate Immunity
    Downloaded from http://cshperspectives.cshlp.org/ on September 28, 2021 - Published by Cold Spring Harbor Laboratory Press The Chemokine System in Innate Immunity Caroline L. Sokol and Andrew D. Luster Center for Immunology & Inflammatory Diseases, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114 Correspondence: [email protected] Chemokines are chemotactic cytokines that control the migration and positioning of immune cells in tissues and are critical for the function of the innate immune system. Chemokines control the release of innate immune cells from the bone marrow during homeostasis as well as in response to infection and inflammation. Theyalso recruit innate immune effectors out of the circulation and into the tissue where, in collaboration with other chemoattractants, they guide these cells to the very sites of tissue injury. Chemokine function is also critical for the positioning of innate immune sentinels in peripheral tissue and then, following innate immune activation, guiding these activated cells to the draining lymph node to initiate and imprint an adaptive immune response. In this review, we will highlight recent advances in understanding how chemokine function regulates the movement and positioning of innate immune cells at homeostasis and in response to acute inflammation, and then we will review how chemokine-mediated innate immune cell trafficking plays an essential role in linking the innate and adaptive immune responses. hemokines are chemotactic cytokines that with emphasis placed on its role in the innate Ccontrol cell migration and cell positioning immune system. throughout development, homeostasis, and in- flammation. The immune system, which is de- pendent on the coordinated migration of cells, CHEMOKINES AND CHEMOKINE RECEPTORS is particularly dependent on chemokines for its function.
    [Show full text]
  • Potent Cytotoxicity of Anti-CD20/CD74 Bispecific Antibodies in Mantle Cell and Other Lymphomas
    From www.bloodjournal.org by guest on September 11, 2016. For personal use only. LYMPHOID NEOPLASIA Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas Pankaj Gupta,1 David M. Goldenberg,2 Edmund A. Rossi,3 Thomas M. Cardillo,1 John C. Byrd,4 Natarajan Muthusamy,4 Richard R. Furman,5 and Chien-Hsing Chang1,3 1Immunomedics Inc, Morris Plains, NJ; 2Garden State Cancer Center, Center for Molecular Medicine and Immunology, Morris Plains, NJ; 3IBC Pharmaceuticals, Morris Plains, NJ; 4Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH; and 5Weill-Cornell Medical College, New York, NY We describe the use of novel bispecific more potent than their parental mAbs in cells and normal B cells from whole blood hexavalent Abs (HexAbs) to enhance anti- vitro. The juxtaposition of CD20 and CD74 ex vivo and significantly extended the sur- cancer immunotherapy. Two bispecific on MCL cells by the HexAbs resulted in vival of nude mice bearing MCL xenografts HexAbs [IgG-(Fab)4 constructed from vel- homotypic adhesion and triggered intra- in a dose-dependent manner, thus indicat- tuzumab (anti-CD20 IgG) and milatu- cellular changes that include loss of mito- ing stability and antitumor activity in vivo. zumab (anti-CD74 IgG)] show enhanced chondrial transmembrane potential, pro- Such bispecific HexAbs may constitute a cytotoxicity in mantle cell lymphoma duction of reactive oxygen species, rapid new class of therapeutic agents for im- (MCL) and other lymphoma/leukemia cell and sustained phosphorylation of ERKs proved cancer immunotherapy, as shown lines, as well as patient tumor samples, and JNK, down-regulation of pAkt and here for MCL and other CD20؉/CD74؉ without a crosslinking Ab, compared with Bcl-xL, actin reorganization, and lyso- malignancies.
    [Show full text]
  • Cell Survival in a Pathway Induced by CD74 Factor/Scatter Factor
    c-Met and Its Ligand Hepatocyte Growth Factor/Scatter Factor Regulate Mature B Cell Survival in a Pathway Induced by CD74 This information is current as Maya Gordin, Melania Tesio, Sivan Cohen, Yael Gore, Frida of September 28, 2021. Lantner, Lin Leng, Richard Bucala and Idit Shachar J Immunol published online 16 July 2010 http://www.jimmunol.org/content/early/2010/07/16/jimmun ol.0902566 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2010/07/16/jimmunol.090256 Material 6.DC1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 28, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published July 16, 2010, doi:10.4049/jimmunol.0902566 The Journal of Immunology c-Met and Its Ligand Hepatocyte Growth Factor/Scatter Factor Regulate Mature B Cell Survival in a Pathway Induced by CD74 Maya Gordin,* Melania Tesio,* Sivan Cohen,* Yael Gore,* Frida Lantner,* Lin Leng,† Richard Bucala,† and Idit Shachar* The signals regulating the survival of mature splenic B cells have become a major focus in recent studies of B cell immunology.
    [Show full text]
  • CD74 Interferes with the Expression of Fas Receptor on the Surface Of
    Berkova et al. Journal of Experimental & Clinical Cancer Research 2014, 33:80 http://www.jeccr.com/content/33/1/80 RESEARCH Open Access CD74 interferes with the expression of fas receptor on the surface of lymphoma cells Zuzana Berkova1, Shu Wang1, Xue Ao1, Jillian F Wise1, Frank K Braun1, Abdol H Rezaeian1, Lalit Sehgal1, David M Goldenberg2,3 and Felipe Samaniego1* Abstract Background: Resistance to Fas-mediated apoptosis limits the efficacy of currently available chemotherapy regimens. We identified CD74, which is known to be overexpressed in hematological malignancies, as one of the factors interfering with Fas-mediated apoptosis. Methods: CD74 expression was suppressed in human B-lymphoma cell lines, BJAB and Raji, by either transduction with lentivirus particles or transfection with episomal vector, both encoding CD74-specific shRNAs or non-target shRNA. Effect of CD74 expression on Fas signaling was evaluated by comparing survival of mice hydrodynamically transfected with vector encoding full-length CD74 or empty vector. Sensitivity of cells with suppressed CD74 expression to FasL, edelfosine, doxorubicin, and a humanized CD74-specific antibody, milatuzumab, was evaluatedbyflowcytometryandcomparedto control cells. Fas signaling in response to FasL stimulation and the expression of Fas signaling components were evaluated by Western blot. Surface expression of Fas was detected by flow cytometry. Results: We determined that cells with suppressed CD74 are more sensitive to FasL-induced apoptosis and Fas signaling-dependent chemotherapies, edelfosine and doxorubicin, than control CD74-expressing cells. On the other hand, expression of full-length CD74 in livers protected the mice from a lethal challenge with agonistic anti-Fas antibody Jo2. A detailed analysis of Fas signaling in cells lacking CD74 and control cells revealed increased cleavage/activation of pro-caspase-8 and corresponding enhancement of caspase-3 activation in the absence of CD74, suggesting that CD74 affects the immediate early steps in Fas signaling at the plasma membrane.
    [Show full text]
  • The Expression of Genes Contributing to Pancreatic Adenocarcinoma Progression Is Influenced by the Respective Environment – Sagini Et Al
    The expression of genes contributing to pancreatic adenocarcinoma progression is influenced by the respective environment – Sagini et al Supplementary Figure 1: Target genes regulated by TGM2. Figure represents 24 genes regulated by TGM2, which were obtained from Ingenuity Pathway Analysis. As indicated, 9 genes (marked red) are down-regulated by TGM2. On the contrary, 15 genes (marked red) are up-regulated by TGM2. Supplementary Table 1: Functional annotations of genes from Suit2-007 cells growing in pancreatic environment Categoriesa Diseases or p-Valuec Predicted Activation Number of genesf Functions activationd Z-scoree Annotationb Cell movement Cell movement 1,56E-11 increased 2,199 LAMB3, CEACAM6, CCL20, AGR2, MUC1, CXCL1, LAMA3, LCN2, COL17A1, CXCL8, AIF1, MMP7, CEMIP, JUP, SOD2, S100A4, PDGFA, NDRG1, SGK1, IGFBP3, DDR1, IL1A, CDKN1A, NREP, SEMA3E SERPINA3, SDC4, ALPP, CX3CL1, NFKBIA, ANXA3, CDH1, CDCP1, CRYAB, TUBB2B, FOXQ1, SLPI, F3, GRINA, ITGA2, ARPIN/C15orf38- AP3S2, SPTLC1, IL10, TSC22D3, LAMC2, TCAF1, CDH3, MX1, LEP, ZC3H12A, PMP22, IL32, FAM83H, EFNA1, PATJ, CEBPB, SERPINA5, PTK6, EPHB6, JUND, TNFSF14, ERBB3, TNFRSF25, FCAR, CXCL16, HLA-A, CEACAM1, FAT1, AHR, CSF2RA, CLDN7, MAPK13, FERMT1, TCAF2, MST1R, CD99, PTP4A2, PHLDA1, DEFB1, RHOB, TNFSF15, CD44, CSF2, SERPINB5, TGM2, SRC, ITGA6, TNC, HNRNPA2B1, RHOD, SKI, KISS1, TACSTD2, GNAI2, CXCL2, NFKB2, TAGLN2, TNF, CD74, PTPRK, STAT3, ARHGAP21, VEGFA, MYH9, SAA1, F11R, PDCD4, IQGAP1, DCN, MAPK8IP3, STC1, ADAM15, LTBP2, HOOK1, CST3, EPHA1, TIMP2, LPAR2, CORO1A, CLDN3, MYO1C,
    [Show full text]
  • Detection of NRG1 Gene Fusions in Solid Tumors
    Author Manuscript Published OnlineFirst on April 15, 2019; DOI: 10.1158/1078-0432.CCR-19-0160 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Title: Detection of NRG1 gene fusions in solid tumors Authors: Sushma Jonna1, Rebecca A. Feldman2, Jeffrey Swensen2, Zoran Gatalica2, Wolfgang M. Korn2, Hossein Borghaei3, Patrick C. Ma4, Jorge Nieva5, Alexander Spira6, Ari Vanderwalde7, Antoinette Wozniak8, Edward S. Kim9, Stephen V. Liu1 Affiliations: 1 Georgetown University, Washington, DC 2 Caris Life Sciences, Phoenix, AZ 3 Fox Chase Cancer Center, Philadelphia, PA 4 WVU Cancer Institute, West Virginia University, Morgantown, WV 5 University of Southern California, Los Angeles, CA 6 Virginia Health Specialists, Fairfax, VA 7 West Cancer Center, Memphis, TN 8 University of Pittsburgh Medical Center, Pittsburgh, PA 9 Atrium Healthcare, Levine Cancer Institute, Charlotte, NC Running Title: NRG1 fusions in solid tumors Keywords: NRG1, Neuregulin-1, gene fusions, NSCLC, RNA-sequencing Financial Support: The authors received no specific funding for this work. Corresponding Author: Stephen V. Liu, MD Georgetown University Lombardi Comprehensive Cancer Center 3800 Reservoir Road NW Washington, DC 20007 Phone: 202-444-2223 Fax: 202-444-7009 Email: [email protected] Conflict of Interest Statement: S. Jonna reports no competing interests. R.A. Feldman, J. Swensen, Z. Gatalica and W.M. Korn are employees of Caris Life Sciences. W.M. Korn reports consulting/advisory role from Merrimack
    [Show full text]
  • Supplementary Information
    Osa et al Supplementary Information Clinical implications of monitoring nivolumab immunokinetics in previously treated non– small cell lung cancer patients Akio Osa, Takeshi Uenami, Shohei Koyama, Kosuke Fujimoto, Daisuke Okuzaki, Takayuki Takimoto, Haruhiko Hirata, Yukihiro Yano, Soichiro Yokota, Yuhei Kinehara, Yujiro Naito, Tomoyuki Otsuka, Masaki Kanazu, Muneyoshi Kuroyama, Masanari Hamaguchi, Taro Koba, Yu Futami, Mikako Ishijima, Yasuhiko Suga, Yuki Akazawa, Hirotomo Machiyama, Kota Iwahori, Hyota Takamatsu, Izumi Nagatomo, Yoshito Takeda, Hiroshi Kida, Esra A. Akbay, Peter S. Hammerman, Kwok-kin Wong, Glenn Dranoff, Masahide Mori, Takashi Kijima, Atsushi Kumanogoh Supplemental Figures 1 – 8 1 Osa et al Supplemental Figure 1. The frequency of nivolumab-bound T cells was maintained in patients who continued treatment. Nivolumab binding in CD8 and CD4 T cells was analyzed at two follow-up points, as indicated, in fresh peripheral blood from three representative cases from protocol 1 that continued treatment. 2 Osa et al Supplemental Figure 2. Long-term follow-up of nivolumab binding to T cells from fresh whole blood. Nivolumab binding was followed up in fresh peripheral blood from an additional case, Pt.7. 3 Osa et al Supplemental Figure 3. Long-term duration of nivolumab binding is due to sustained circulation of residual nivolumab in plasma. (A) PBMCs acquired from Pt.8 and 9 at pretreatment (pre PBMCs) and after a single dose (post 1 PBMCs) were cultured in regular medium without nivolumab (top and middle). Pre PBMCs were also incubated with 10 µg/ml nivolumab in vitro before the cultures were started (bottom). Nivolumab binding status was monitored at the indicated time points.
    [Show full text]
  • And CD74-Dependent Manner Regulates B Cell Chronic Lymphocytic Leukemia Survival
    IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival Inbal Binsky*, Michal Haran†, Diana Starlets*, Yael Gore*, Frida Lantner*, Nurit Harpaz†, Lin Leng‡, David M. Goldenberg§, Lev Shvidel†, Alain Berrebi†, Richard Bucala‡, and Idit Shachar*¶ *Department of Immunology, Weizmann Institute of Science, Rehovot 76100, Israel; †Hematology Institute, Kaplan Medical Center, P.O. Box 1, Rehovot 76100, Israel; ‡Department of Medicine, Yale University School of Medicine, New Haven, CT 06520; and §Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ 07109 Edited by Carlo M. Croce, Ohio State University, Columbus, OH, and approved July 2, 2007 (received for review February 20, 2007) Chronic lymphocytic leukemia (CLL) is a malignant disease of small results in secretion of IL-8, which regulates B-CLL survival. Block- mature lymphocytes. Previous studies have shown that CLL B ing this pathway induces cell death. Thus, CD74 expressed on the lymphocytes express relatively large amounts of CD74 mRNA surface of B-CLL cells plays a critical role in regulating the survival relative to normal B cells. In the present study, we analyzed the of these malignant cells. molecular mechanism regulated by CD74 in B-CLL cells. The results presented here show that activation of cell-surface CD74, ex- Results pressed at high levels from an early stage of the disease by its CD74 Expression Is Highly Up-Regulated in B-CLL. To determine natural ligand, macrophage migration-inhibition factor (MIF), ini- whether activation of the cell-surface protein CD74 in B-CLL cells tiates a signaling cascade that contributes to tumor progression.
    [Show full text]